Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

PeptimAIze PeptimAIze: Revolutionazing Peptide Design through Multi-Property Optimization and Explainable AI

Coordinator
Imperial College of Science Technology and Medicine, United Kingdom
Runs
1 September 2027 to 31 August 2029
Status
Running
EU funding
€260k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101269352

What the project is doing

In the project's own words, from its summary on CORDIS.

PeptimAIze aims to develop a deep learning model capable of generating therapeutic peptides for inhibiting protein-protein interactions (PPIs). Many PPIs are essential to key physiological and pathological processes, making these interactions ideal targets for selective intervention in several human diseases, including cancer and bacterial infections. However, the therapeutic potential of peptides is often limited by unfavorable physicochemical properties, such as low solubility and poor bioavailability.

Current peptide discovery approaches are time- and resource-intensive, generating significant waste through iterative and labour-intensive screening of compound batches across multiple optimisation rounds to experimentally achieve the desired physicochemical properties. While deep learning and generative models have recently emerged for on-demand peptide design, most focus on a single aspect, typically binding affinity, disregarding physicochemical properties and experimental validation.

PeptimAIze addresses these gaps by developing a multi-objective deep learning model based on protein language processing that designs peptides by co-optimising binding to the target and the physicochemical properties necessary for optimal administrability and bioavailability. The model will incorporate explainable AI techniques to enhance interpretability and reveal which amino acids in the peptide sequence are associated with the tuning of each considered property.

A key step will be the wet-lab validation of the model on targets responsible for vital bacterial functions (Doc/Phd) and cancer development (p53/MDM2 and Bcl-xL/Bak), demonstrating real-world lab applicability. To maximise impact and usability, the model will be deployed through an intuitive, user-friendly app, enabling researchers in academia and industry to design peptides with tailored properties.

Topics

Who is involved

OrganisationCityCountryRole
Imperial College of Science Technology and MedicineLondonUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI